New Study On Sulfatase-2 May Bring New Treatment For Rehumatoid arthritis

Sep, 2022 - By SMI

The limitations of the rheumatoid arthritis drugs that are now available, many of which have significant side effects, may be resolved with the development of new therapies based on sulfatase-2.

Different types of arthritis exist, and they each have a unique origin. Osteoarthritis, the most prevalent type of arthritis, is brought on by injury to the joint, infection of the joint, or advancing age. The autoimmune disorders psoriatic arthritis and rheumatoid arthritis, is a a long-term condition where the body's own joint tissues are attacked by the immune system. Sulfatase-2 is a protein that has been identified by researchers as being crucial in the harm rheumatoid arthritis causes. Salah-Uddin Ahmed, the senior author and a professor in the College of Pharmacy and Pharmaceutical Sciences at Washington State University, conducted this study recently. He asserts that individuals may eventually get resistant to these medications, rendering them ineffective for them.

However, many of the treatments that are now on the market target tumour necrosis factor, one of the key inflammatory proteins that fuels rheumatoid arthritis. Now researchers focus on Sulfatases, such as sulfatase-2, have been thoroughly researched for their roles in several forms of cancer. The study team took sulfatase-2 out of one group of joint-lining cells from rheumatoid arthritis patients before activating all of the cells with the inflammatory TNF-alpha. They discovered that sulfatase-2-deficient cells did not exhibit the same heightened inflammatory response to TNF-alpha as cells that were left intact.

The findings, which are the result of four years' worth of study, allow for further animal trials to determine whether suppressing sulfatase-2 reduces the symptoms of rheumatoid arthritis. This may ultimately lead to the development of innovative combination medications that aim to stop bone loss, cartilage damage, and joint abnormalities by simultaneously inhibiting sulfatase-2 and other inflammatory proteins.. The limitations of the rheumatoid arthritis drugs currently available on the market, many of which have severe side effects, may be addressed with the help of these remedies.